Cargando…

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

BACKGROUND: Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied. We aimed to systematically carry out a direct comparison of outcomes observed with prasugrel versus clopidogrel following PCI. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bundhun, Pravesh Kumar, Huang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932806/ https://www.ncbi.nlm.nih.gov/pubmed/29720092 http://dx.doi.org/10.1186/s12872-018-0820-6

Ejemplares similares

Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
por: Jiang, Zhiming, et al.
Publicado: (2022)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment
por: Shoji, Satoshi, et al.
Publicado: (2020)

Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI: A systematic review and meta-analysis of randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2016)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Short-Term Versus Long-Term Adverse Cardiovascular Outcomes Post Percutaneous Coronary Intervention in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Simple Meta-Analysis
por: Lu, Hongtao, et al.
Publicado: (2019)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 – 2016)
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
por: Crimi, Gabriele, et al.
Publicado: (2019)

Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
por: Liu, Ping-Yen, et al.
Publicado: (2021)

Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2015)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel
por: Geisler, Tobias, et al.
Publicado: (2015)

Adverse Cardiovascular Outcomes associated with Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention with Everolimus Eluting Stents: A Meta-Analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2016)

Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases
por: Hagiwara, Hiromi, et al.
Publicado: (2020)

Comparing the adverse clinical outcomes associated with fraction flow reserve-guided versus angiography-guided percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2016)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
por: Chen, Wenwen, et al.
Publicado: (2021)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2016)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
por: Hajsadeghi, Shokoufeh, et al.
Publicado: (2016)

Bleeding events and maintenance dose of prasugrel: BLESS pilot study
por: Carrabba, Nazario, et al.
Publicado: (2016)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2018)

Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry
por: Khayata, Mohamed, et al.
Publicado: (2017)

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention
por: Jin, Han-Young, et al.
Publicado: (2014)

Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 100 Studies
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2015)

Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention
por: Ahn, Kye Taek, et al.
Publicado: (2019)

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
por: Lee, Dongwhane, et al.
Publicado: (2018)

Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery and the SYNTAX score: A systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery
por: Huo, Bright, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1sklcoe42eces1antqc7d8101n